Inhibiting Caspase-1 Enzyme Shows Promise in Preventing Lung Cancer Development in Mice

A new study has found that blocking inflammatory responses in the lungs by inhibiting the enzyme 'caspase-1' can significantly reduce the incidence of lung cancer in genetically modified mice. This research, published in *Science Advances*, suggests a potential pathway for future lung cancer prevention treatments, especially since a caspase-1 inhibitor drug (Belnacasan) has already undergone human clinical trials for other conditions, potentially accelerating its development as a preventive agent. The study originated from an unexpected observation in a 2017 clinical trial where cardiovascular disease patients receiving an antibody suppressing the inflammatory substance 'IL-1 beta' showed lower lung cancer rates. Researchers confirmed higher caspase-1 activity in tumor areas of mice and fluid samples from lung cancer patients.